Gastrointestinal Therapeutics Market Research Report 2021, Size, Share, Trends and Forecast to 2026
Gastrointestinal Therapeutics Market Research Report 2021, Size, Share, Trends and Forecast to 2026
Published by IMARC Services Private Limited
Posted on September 13, 2021
According to the latest report by IMARC Group, titled “Gastrointestinal Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026,” the global gastrointestinal therapeutics market size grew at a CAGR of around 7% during 2015-2020. Looking forward, IMARC Group expects the global gastrointestinal therapeutics market to exhibit moderate growth during 2021-2026. Gastrointestinal disorders refer to medical conditions that are related to the gastrointestinal tract and the functioning of accessory digestive organs, such as the pancreas, stomach, small and large intestines, gall bladder and rectum. Some of the most common gastrointestinal disorders may include indigestion, constipation, peptic ulcer diseases, and irritable bowel syndrome, which are usually characterized by heartburn, stomachache, bloating, vomiting, and nausea. Gastrointestinal therapeutics is a branch of medicine that aids in the treatment of such ailments by reducing gastric acidity, improving digestion and properly regulating water flow in the gastrointestinal tract. These therapeutics include various over-the-counter (OTC) and prescription drugs, such as laxatives, antacids, antiemetics, antidiarrheal agents, and antiulcer agents.
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviors of the consumers globally–our estimates about the latest market trends and forecast values after considering the impact of this pandemic.
Global Gastrointestinal Therapeutics Market Trends:
The global market is primarily driven by the rising prevalence of gastrointestinal diseases across the globe. Several ailments, such as constipation, diarrhea and gastroesophageal reflux disease (GERD), are commonly caused due to the shifting lifestyle preferences and the changing dietary patterns of the masses that have led to an increase in the consumption of unhealthy food. This, along with the rising healthcare expenditure, is providing a boost to the uptake of gastrointestinal therapeutics on the global level. Moreover, there has been a considerable rise in the geriatric population that is more prone to develop these gastrointestinal conditions. This, coupled with the easy availability of OTC gastrointestinal drugs through organized online and offline pharmacies, is expected to create a positive outlook for the market. The increasing usage of biosimilars and cellular therapies for the treatment of gastrointestinal disorders that offer personalized and targeted treatment to the patients is also creating a positive outlook for the market. Some of the other factors contributing to the market growth include the rising utilization of regenerative medicines, extensive research and development (R&D) activities, increasing numbers of clinical trials with accurate results to offer innovative therapies to the patients, and the significant developments in the overall healthcare infrastructure.
The competitive landscape of the industry has also been examined along with the profiles of the key players.
Abbott Laboratories
AbbVie Inc.
AstraZeneca Plc
Bausch Health Companies Inc.
Bayer Aktiengesellschaft
GlaxoSmithKline Plc
Janssen Biotech Inc. (Johnson & Johnson)
Novo Nordisk A/S
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceuticals.
Breakup by Type:
Branded
Generic
Breakup by Route of Administration:
Oral
Intravenous
Others
Breakup by Application:
Ulcerative Colitis
Crohn’s Disease
GERD
Others
Breakup by Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Breakup by Region:
North America (United States, Canada)
Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
Europe (Germany, France, United Kingdom, Italy, Spain, Others)
Latin America (Brazil, Mexico, Others)
Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)
Key highlights of the Report:
Market Performance (2015-2020)
Market Outlook (2021-2026)
Porter’s Five Forces Analysis
Market Drivers and Success Factors
SWOT Analysis
Value Chain
Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group 30 N Gould St, Ste R Sheridan, WY (Wyoming) 82801 USA Email: Sales@imarcgroup.com Tel No:(D) +91 120 433 0800 Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
According to the latest report by IMARC Group, titled “Gastrointestinal Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026,” the global gastrointestinal therapeutics market size grew at a CAGR of around 7% during 2015-2020. Looking forward, IMARC Group expects the global gastrointestinal therapeutics market to exhibit moderate growth during 2021-2026. Gastrointestinal disorders refer to medical conditions that are related to the gastrointestinal tract and the functioning of accessory digestive organs, such as the pancreas, stomach, small and large intestines, gall bladder and rectum. Some of the most common gastrointestinal disorders may include indigestion, constipation, peptic ulcer diseases, and irritable bowel syndrome, which are usually characterized by heartburn, stomachache, bloating, vomiting, and nausea. Gastrointestinal therapeutics is a branch of medicine that aids in the treatment of such ailments by reducing gastric acidity, improving digestion and properly regulating water flow in the gastrointestinal tract. These therapeutics include various over-the-counter (OTC) and prescription drugs, such as laxatives, antacids, antiemetics, antidiarrheal agents, and antiulcer agents.
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviors of the consumers globally–our estimates about the latest market trends and forecast values after considering the impact of this pandemic.
Global Gastrointestinal Therapeutics Market Trends:
The global market is primarily driven by the rising prevalence of gastrointestinal diseases across the globe. Several ailments, such as constipation, diarrhea and gastroesophageal reflux disease (GERD), are commonly caused due to the shifting lifestyle preferences and the changing dietary patterns of the masses that have led to an increase in the consumption of unhealthy food. This, along with the rising healthcare expenditure, is providing a boost to the uptake of gastrointestinal therapeutics on the global level. Moreover, there has been a considerable rise in the geriatric population that is more prone to develop these gastrointestinal conditions. This, coupled with the easy availability of OTC gastrointestinal drugs through organized online and offline pharmacies, is expected to create a positive outlook for the market. The increasing usage of biosimilars and cellular therapies for the treatment of gastrointestinal disorders that offer personalized and targeted treatment to the patients is also creating a positive outlook for the market. Some of the other factors contributing to the market growth include the rising utilization of regenerative medicines, extensive research and development (R&D) activities, increasing numbers of clinical trials with accurate results to offer innovative therapies to the patients, and the significant developments in the overall healthcare infrastructure.
The competitive landscape of the industry has also been examined along with the profiles of the key players.
Abbott Laboratories
AbbVie Inc.
AstraZeneca Plc
Bausch Health Companies Inc.
Bayer Aktiengesellschaft
GlaxoSmithKline Plc
Janssen Biotech Inc. (Johnson & Johnson)
Novo Nordisk A/S
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceuticals.
Breakup by Type:
Branded
Generic
Breakup by Route of Administration:
Oral
Intravenous
Others
Breakup by Application:
Ulcerative Colitis
Crohn’s Disease
GERD
Others
Breakup by Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Breakup by Region:
North America (United States, Canada)
Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
Europe (Germany, France, United Kingdom, Italy, Spain, Others)
Latin America (Brazil, Mexico, Others)
Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)
Key highlights of the Report:
Market Performance (2015-2020)
Market Outlook (2021-2026)
Porter’s Five Forces Analysis
Market Drivers and Success Factors
SWOT Analysis
Value Chain
Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group 30 N Gould St, Ste R Sheridan, WY (Wyoming) 82801 USA Email: Sales@imarcgroup.com Tel No:(D) +91 120 433 0800 Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800